First-quarter earnings for medical products maker Baxter International rose 26%, buoyed by strong growth in its Bioscience business sales, the company said. Baxter's chairman and CEO said the positive performance would allow the company to speed up research and development efforts and make investments throughout the year.

Related Summaries